Abstract 1898: LNCB74 is a potent and safe next-generation antibody-drug-conjugate utilizing a cancer selective linker for the treatment of B7-H4 expressing cancers

• Published in: Cancer research (Chicago, Ill.) Vol. 84; no. 6_Supplement; p. 1898
• Main Authors: Fitzgerald, Daniel P., Doan, Duc N., Peacock, Riley B., Kahan, Shannon M., Lomash, Suvendu, Slocum, Stephen, Jung, Kwang Hwa, Oh, Hwanhee, Meza, Ingrid, Manzanarez, Yanira, Selvam, Shanmugam, Flies, Dallas B., Chung, Chul-Woong, Langermann, Sol
• Format: Journal Article
• Language: English
• Published: 22.03.2024

Abstract The B7 family protein B7-H4 is highly expressed on a range of solid tumors including breast, ovarian, and endometrial cancers, where it may play a role in immune evasion. In non-cancerous tissues, B7-H4 expression is limited, suggesting it may be a potential target for an antibody drug conj...